GDTC

CytoMed Therapeutics Limited Ordinary Shares

1.31

USD

GDTC Earnings Reports

Positive Surprise Ratio

No Data Available for GDTC

Next Report

Date of Next Report

Apr 28, 2026

Estimate for Q4 25 (Revenue/ EPS)

$132.60K

-$0.04

Implied change from Q2 25 (Revenue/ EPS)

Implied change from Q4 24 (Revenue/ EPS)

CytoMed Therapeutics Limited Ordinary Shares earnings per share and revenue

On Nov 14, 2025, GDTC reported earnings of -- USD per share (EPS) for Q2 25, -- the estimate of -0.04 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 132.60 thousand, with a --% difference.

Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.04 USD, with revenue projected to reach 132.60 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

FAQ

What were CytoMed Therapeutics Limited Ordinary Shares's earnings and revenue for the latest quarter Q2 2025?

For Q2 2025, CytoMed Therapeutics Limited Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to CytoMed Therapeutics Limited Ordinary Shares's Q2 2025 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is CytoMed Therapeutics Limited Ordinary Shares expected to report next?

The next earning report is scheduled for Apr 28, 2026.

What are the forecasts for CytoMed Therapeutics Limited Ordinary Shares's next earnings report?

Based on 3 analysts, CytoMed Therapeutics Limited Ordinary Shares is expected to report EPS of -$0.04 and revenue of $132.60K for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.